

Ronald Go

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6359821/publications.pdf>

Version: 2024-02-01

541
papers

11,619
citations

38660

50
h-index

42291

92
g-index

546
all docs

546
docs citations

546
times ranked

12432
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics and risk factors for thrombosis in <scp>POEMS</scp> syndrome: A retrospective evaluation of 230 patients. American Journal of Hematology, 2022, 97, 209-215.	2.0	5
2	Sustained, complete response to pexidartinib in a patient with <scp><i>CSF1R</i></scp>â€ˆmutated Erdheimâ€ˆChester disease. American Journal of Hematology, 2022, 97, 293-302.	2.0	9
3	Impact of a Multidisciplinary Tumor Board on the Care of Patients with Histiocytic Disorders: The Histiocytosis Working Group experience. Oncologist, 2022, 27, 144-148.	1.9	3
4	Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. American Journal of Hematology, 2022, , .	2.0	5
5	A <scp>populationâ€ˆbased</scp> study of acute panmyelosis with myelofibrosis in the United States: 2004â€ˆ2015. American Journal of Hematology, 2022, 97, .	2.0	1
6	Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approval. Leukemia Research, 2022, 112, 106770.	0.4	4
7	Female Representation in Clinical Practice Guideline Panels in 2 Major Cancer Organizations. Oncology, 2022, 36, 59-63.	0.4	0
8	A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer Journal, 2022, 12, 21.	2.8	30
9	Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. American Journal of Hematology, 2022, , .	2.0	2
10	Isolated anemia in patients with large granular lymphocytic leukemia (LGLL). Blood Cancer Journal, 2022, 12, 30.	2.8	4
11	International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood, 2022, 139, 2601-2621.	0.6	63
12	Autoimmune Hemolytic Anemia: Diagnosis and Differential Diagnosis. Hematology/Oncology Clinics of North America, 2022, 36, 315-324.	0.9	6
13	Multimodality imaging of cardiac involvement in Erdheimâ€ˆChester disease. European Heart Journal Cardiovascular Imaging, 2022, , .	0.5	0
14	Economic Cost and Sustainability of Oral Therapies in Precision Oncology. JCO Oncology Practice, 2022, 18, e1247-e1254.	1.4	6
15	Clinical features and outcomes of non-pulmonary unifocal adult Langerhans cell histiocytosis. Blood Cancer Journal, 2022, 12, .	2.8	3
16	Impact of high-dose melphalan followed by autologous stem cell transplant in producing MRD negative complete response in newly diagnosed multiple myeloma.. Journal of Clinical Oncology, 2022, 40, e20001-e20001.	0.8	0
17	Sarcopenia identified by computed tomography (CT) imaging using a machine learningâ€ˆbased convolutional neural network (CNN) algorithm impacts survival in patients with newly diagnosed multiple myeloma (NDMM).. Journal of Clinical Oncology, 2022, 40, 110-110.	0.8	1
18	Insurance-based disparities in Waldenström Macroglobulinemia: An NCDB analysis.. Journal of Clinical Oncology, 2022, 40, e19562-e19562.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Clinical and therapeutic implications of BRAF fusions in histiocytic disorders. Blood Cancer Journal, 2022, 12, .	2.8	7
20	Medicare expenditures for discarded oncology therapies.. Journal of Clinical Oncology, 2022, 40, 6552-6552.	0.8	0
21	Changes in Frequency of Surveillance Imaging of Survivors of Diffuse Large B-Cell Lymphoma After the American Society of Hematology Choosing Wisely Recommendations. JCO Oncology Practice, 2021, 17, e490-e496.	1.4	1
22	Leukocytosis and Tobacco Use: An Observational Study of Asymptomatic Leukocytosis. American Journal of Medicine, 2021, 134, e31-e35.	0.6	13
23	Category of evidence and consensus underlying National Comprehensive Cancer Network guidelines: Is there evidence of progress?. International Journal of Cancer, 2021, 148, 429-436.	2.3	12
24	Teaching NeuroImages: Brain and Skin Involvement in Erdheim-Chester Disease. Neurology, 2021, 96, e1590-e1592.	1.5	1
25	Characterization and prognostic implication of delayed complete response in AL amyloidosis. European Journal of Haematology, 2021, 106, 354-361.	1.1	4
26	Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. European Journal of Haematology, 2021, 106, 433-436.	1.1	3
27	Implications of detecting serum monoclonal protein by MASSâ€fix following stem cell transplantation in multiple myeloma. British Journal of Haematology, 2021, 193, 380-385.	1.2	21
28	Monitoring Ravulizumab effect on complement assays. Journal of Immunological Methods, 2021, 490, 112944.	0.6	9
29	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (<scp>VRd</scp>) as firstâ€line therapy in multiple myeloma. American Journal of Hematology, 2021, 96, 330-337.	2.0	13
30	Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia. Leukemia and Lymphoma, 2021, 62, 308-315.	0.6	3
31	Level of Scientific Evidence Underlying the National Comprehensive Cancer Network Clinical Practice Guidelines for Hematologic Malignancies: Are We Moving Forward?. Oncology, 2021, 35, 390-396.	0.4	3
32	Singleâ€agent cladribine as an effective frontâ€line therapy for adults with Langerhans cell histiocytosis. American Journal of Hematology, 2021, 96, E146-E150.	2.0	21
33	Prognostic restaging after treatment initiation in patients with AL amyloidosis. Blood Advances, 2021, 5, 1029-1036.	2.5	9
34	Coagulation Abnormalities in Light Chain Amyloidosis. Mayo Clinic Proceedings, 2021, 96, 377-387.	1.4	12
35	The Reply. American Journal of Medicine, 2021, 134, e229.	0.6	0
36	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. Mayo Clinic Proceedings, 2021, 96, 677-687.	1.4	16

#	ARTICLE	IF	CITATIONS
37	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. <i>Blood Cancer Journal</i> , 2021, 11, 50.	2.8	25
38	A population-based study of acute panmyelosis with myelofibrosis in the United States: 2004 to 2015.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19003-e19003.	0.8	0
39	Impact of stratifying levels of serum lactate dehydrogenase (LDH) at diagnosis on the overall survival (OS) in newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , 2021, 39, e20016-e20016.	0.8	0
40	Phenotypes and prognostic factors in adults with Langerhans cell histiocytosis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7049-7049.	0.8	0
41	<i>BRAF</i> ^{V600E} frequency and impact on outcomes in adults with langerhans cell histiocytosis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7050-7050.	0.8	0
42	Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design. <i>Leukemia</i> , 2021, 35, 3604-3607.	3.3	8
43	Trends in female representation in clinical practice guidelines (CPGs) among major cancer organizations.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11006-11006.	0.8	0
44	Conflicts of interest (COI) among the UpToDate oncology management authors.. <i>Journal of Clinical Oncology</i> , 2021, 39, e13573-e13573.	0.8	1
45	Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2021, 96, 945-953.	2.0	12
46	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1546-1577.	1.4	32
47	Interpreting sulfhemoglobin and methemoglobin in patients with cyanosis: An overview of patients with hemoglobin variants. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 837-844.	0.7	10
48	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 451-460.e2.	0.2	9
49	Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 589.e1-589.e6.	0.6	3
50	Immune-related hematologic adverse events in the context of immune checkpoint inhibitor therapy. <i>American Journal of Hematology</i> , 2021, 96, E362-E367.	2.0	4
51	Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 2753-2759.	2.5	13
52	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2021, 62, 3011-3018.	0.6	2
53	Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. <i>American Journal of Hematology</i> , 2021, 96, 1131-1136.	2.0	21
54	Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. <i>American Journal of Hematology</i> , 2021, 96, 1450-1460.	2.0	19

#	ARTICLE	IF	CITATIONS
55	Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2021, 195, 210-216.	1.2	12
56	Langerhans cell histiocytosis with lung involvement in isolation and multisystem disease: Staging, natural history, and comparative survival. <i>American Journal of Hematology</i> , 2021, 96, 1604-1610.	2.0	18
57	The economic cost and sustainability of the precision oncology promise.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7-7.	0.8	1
58	Acute Pancreatitis From Treatment With BRAF Inhibitors in Erdheim-Chester Disease. <i>Pancreas</i> , 2021, 50, e6-e8.	0.5	2
59	Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort. <i>American Journal of Hematology</i> , 2021, 96, 446-454.	2.0	8
60	Rosai-Dorfman Disease Displays a Unique Monocyte-Macrophage Phenotype Characterized by Expression of OCT2. <i>American Journal of Surgical Pathology</i> , 2021, 45, 35-44.	2.1	52
61	A population-based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data from a Mayo Clinic single institutional series. <i>American Journal of Hematology</i> , 2021, 96, E464-E468.	2.0	9
62	Recommendations for Managing Adults With Histiocytic Neoplasms: New NCCN Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1355-1357.	2.3	2
63	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFN γ -NIS). <i>Blood</i> , 2021, 138, 1333-1333.	0.6	0
64	Prognostic Role of IL-6 in POEMS Syndrome. <i>Blood</i> , 2021, 138, 2700-2700.	0.6	0
65	Efficacy of Cobimetinib in Rosai-Dorfman Disease. <i>Blood</i> , 2021, 138, 1506-1506.	0.6	1
66	Impact of Achieving an Early Complete Response in Multiple Myeloma and Predictors of Subsequent Outcome. <i>Blood</i> , 2021, 138, 3773-3773.	0.6	0
67	The Sustainability of Price Dynamics in Precision Hematology. <i>Blood</i> , 2021, 138, 114-114.	0.6	0
68	Classical and Non-Classical Phenotypes of Erdheim-Chester Disease: Correlating Clinical, Radiographic, and Genotypic Findings. <i>Blood</i> , 2021, 138, 2566-2566.	0.6	0
69	Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1277-1303.	2.3	26
70	Mimics of Erdheim-Chester disease. <i>British Journal of Haematology</i> , 2021, , .	1.2	3
71	Evidence of Classical Complement Pathway Involvement in a Subset of Patients with Warm Autoimmune Hemolytic Anemia. <i>Blood</i> , 2021, 138, 2001-2001.	0.6	2
72	Histopathologic Characterization of Vexas Syndrome. <i>Blood</i> , 2021, 138, 4656-4656.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Tumor Mutational Burden in Histiocytic Neoplasms. <i>Blood</i> , 2021, 138, 3634-3634.	0.6	0
74	BRAF Fusions in Histiocytic Disorders: Frequency and Clinical Characteristics. <i>Blood</i> , 2021, 138, 2582-2582.	0.6	1
75	“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience. <i>Blood Cancer Journal</i> , 2021, 11, 196.	2.8	28
76	Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by <i>MAP2K1</i> . <i>Haematologica</i> , 2020, 105, e5-e8.	1.7	34
77	Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. <i>Haematologica</i> , 2020, 105, 348-357.	1.7	105
78	Association between anemia and hematological indices with mortality among cardiac intensive care unit patients. <i>Clinical Research in Cardiology</i> , 2020, 109, 616-627.	1.5	18
79	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 13-16.	1.4	25
80	Influence of Sociodemographic Factors on Treatment Decisions in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e115-e129.	1.1	19
81	Association between facility volume and mortality of patients with classic Hodgkin lymphoma. <i>Cancer</i> , 2020, 126, 757-764.	2.0	5
82	Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. <i>British Journal of Haematology</i> , 2020, 188, 394-403.	1.2	41
83	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. <i>American Journal of Hematology</i> , 2020, 95, 4-9.	2.0	14
84	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 53-56.	0.2	8
85	Enhancing the ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. <i>American Journal of Hematology</i> , 2020, 95, 310-315.	2.0	37
86	Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity. <i>American Journal of Hematology</i> , 2020, 95, E60-E62.	2.0	4
87	Impact of MYD88 ^{L265P} mutation status on histological transformation of Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , 2020, 95, 274-281.	2.0	33
88	Revisiting complete response in light chain amyloidosis. <i>Leukemia</i> , 2020, 34, 1472-1475.	3.3	15
89	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. <i>Leukemia</i> , 2020, 34, 1135-1143.	3.3	29
90	Prevalence of and Recovery From Anemia Following Hospitalization for Critical Illness Among Adults. <i>JAMA Network Open</i> , 2020, 3, e2017843.	2.8	41

#	ARTICLE	IF	CITATIONS
91	Efficacy of BRAF-Inhibitor Therapy in <i>BRAF</i> <i>V600E</i> -Mutated Adult Langerhans Cell Histiocytosis. <i>Oncologist</i> , 2020, 25, 1001-1004.	1.9	25
92	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 6581-6588.	3.2	32
93	Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 95.	2.8	3
94	Predictors of short-term survival in Waldenström Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2975-2979.	0.6	2
95	Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. <i>American Journal of Hematology</i> , 2020, 95, 1280-1287.	2.0	17
96	Low-dose vemurafenib monotherapy in <i>BRAF</i> ^{V600E} -mutated Erdheim-Chester disease. <i>Leukemia and Lymphoma</i> , 2020, 61, 2733-2737.	0.6	9
97	Hapticophagia: Tactile chew cravings in iron deficiency anemia. <i>American Journal of Hematology</i> , 2020, 95, E107-E108.	2.0	2
98	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. <i>Blood Advances</i> , 2020, 4, 3509-3519.	2.5	58
99	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. <i>Blood Cancer Journal</i> , 2020, 10, 82.	2.8	59
100	Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 87.	2.8	13
101	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. <i>Blood Cancer Journal</i> , 2020, 10, 52.	2.8	8
102	Venetoclax for the treatment of translocation (11;14) AL amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, 55.	2.8	36
103	Financial conflicts of interest among National Comprehensive Cancer Network clinical practice guideline panelists in 2019. <i>Cancer</i> , 2020, 126, 3742-3749.	2.0	11
104	Monoclonal Gammopathy of Undetermined Significance: Indications for Prediagnostic Testing, Subsequent Diagnoses, and Follow-up Practice at Mayo Clinic. <i>Mayo Clinic Proceedings</i> , 2020, 95, 944-954.	1.4	7
105	A population-based study of chronic neutrophilic leukemia in the United States. <i>Blood Cancer Journal</i> , 2020, 10, 68.	2.8	8
106	Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2020, 55, 1297-1304.	1.3	5
107	Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 1592-1600.	0.6	17
108	Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis. <i>Blood Cancer Journal</i> , 2020, 10, 33.	2.8	26

#	ARTICLE	IF	CITATIONS
109	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. <i>American Journal of Hematology</i> , 2020, 95, 637-642.	2.0	12
110	A population-based study of chronic eosinophilic <scp>leukemia</scp> otherwise specified in the United States. <i>American Journal of Hematology</i> , 2020, 95, E257.	2.0	6
111	Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. <i>American Journal of Hematology</i> , 2020, 95, 1170-1179.	2.0	19
112	Bone marrow findings in Erdheim-Chester disease: increased prevalence of chronic myeloid neoplasms. <i>Haematologica</i> , 2020, 105, e84-e86.	1.7	12
113	Gender Differences in Faculty Rank and Leadership Positions Among Hematologists and Oncologists in the United States. <i>JCO Oncology Practice</i> , 2020, 16, e507-e516.	1.4	29
114	Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, 20.	2.8	26
115	43-Year-Old Man With Polyuria and Bone Pain. <i>Mayo Clinic Proceedings</i> , 2020, 95, e13-e18.	1.4	0
116	The significance of genetic mutations and their prognostic impact on patients with incidental finding of isolated del(20q) in bone marrow without morphologic evidence of a myeloid neoplasm. <i>Blood Cancer Journal</i> , 2020, 10, 7.	2.8	14
117	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. <i>Blood Cancer Journal</i> , 2020, 10, 4.	2.8	18
118	Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. <i>American Journal of Hematology</i> , 2020, 95, 497-502.	2.0	35
119	Glycosylation of immunoglobulin light chains is highly prevalent in cold agglutinin disease. <i>American Journal of Hematology</i> , 2020, 95, E222-E225.	2.0	15
120	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 596-601.	0.2	15
121	The differential diagnosis of basophilia in patients undergoing <scp>BCR</scp>-<scp>ABL</scp> testing. <i>American Journal of Hematology</i> , 2020, 95, E216-E217.	2.0	6
122	Utility of serum free light chain ratio in response definition in patients with multiple myeloma. <i>Blood Advances</i> , 2020, 4, 322-326.	2.5	8
123	Immune-Related Hematologic Adverse Events in the Context of Checkpoint Inhibitors. <i>Blood</i> , 2020, 136, 31-32.	0.6	1
124	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis. <i>Blood</i> , 2020, 136, 52-53.	0.6	4
125	MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. <i>Blood</i> , 2020, 136, 48-49.	0.6	2
126	Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2020, 136, 36-37.	0.6	4

#	ARTICLE	IF	CITATIONS
127	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). Blood, 2020, 136, 30-31.	0.6	4
128	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Blood, 2020, 136, 7-8.	0.6	1
129	Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM). Blood, 2020, 136, 12-13.	0.6	3
130	Spectrum of Second Primary Malignancies in Pediatric and Adult Langerhans Cell Histiocytosis Cases. Blood, 2020, 136, 51-52.	0.6	2
131	Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood, 2020, 135, 1929-1945.	0.6	191
132	Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Advances, 2020, 4, 2236-2244.	2.5	20
133	Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma. Blood, 2020, 136, 27-28.	0.6	0
134	The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma. Blood, 2020, 136, 9-10.	0.6	0
135	Risk of Mortality and Leukemic Transformation in Primary Myelofibrosis before and after Ruxolitinib Approval. Blood, 2020, 136, 28-28.	0.6	2
136	Detection of Monoclonal Immunoglobulin By Mass Spectrometry in Patients Evaluated for Thrombotic Microangiopathy (TMA). Blood, 2020, 136, 17-17.	0.6	0
137	A Population-Based Study of Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis in the United States from 2001-2015. Blood, 2020, 136, 48-48.	0.6	0
138	The Role of Staging Evaluation at Initial Diagnosis of Adult Patients with Clinically Isolated Pulmonary Langerhans Cell Histiocytosis. Blood, 2020, 136, 45-45.	0.6	0
139	A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. Blood, 2020, 136, 44-45.	0.6	0
140	Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma. Blood, 2020, 136, 15-16.	0.6	0
141	Determination of Relapse Risk By Complement Gene Variants after Eculizumab Discontinuation in Complement-Mediated Thrombotic Microangiopathy: A Retrospective Review. Blood, 2020, 136, 25-26.	0.6	1
142	Level of Scientific Evidence Underlying Recommendations from the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Hematologic Malignancies: Are We Moving Forward?. Blood, 2020, 136, 32-32.	0.6	0
143	Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis. Blood, 2020, 136, 14-15.	0.6	0
144	Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis. Blood, 2020, 136, 6-7.	0.6	0

#	ARTICLE	IF	CITATIONS
145	A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 21-22.	0.6	0
146	Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients. <i>Blood</i> , 2020, 136, 31-32.	0.6	1
147	A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015. <i>Blood</i> , 2020, 136, 30-31.	0.6	0
148	Waldenström Macroglobulinemia in the Very Elderly (≥75 years): Clinical Characteristics and Outcomes. <i>Blood</i> , 2020, 136, 44-45.	0.6	8
149	Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 306-311.	2.0	18
150	Predictors of survival, treatment patterns, and outcomes in histiocytic sarcoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 553-555.	0.6	12
151	T cell/histiocyte-rich large B cell lymphoma: incidence, demographic disparities, and long-term outcomes. <i>British Journal of Haematology</i> , 2019, 185, 140-142.	1.2	9
152	A population-based analysis of second primary malignancies in T-cell neoplasms. <i>British Journal of Haematology</i> , 2019, 185, 338-342.	1.2	6
153	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. <i>Bone Marrow Transplantation</i> , 2019, 54, 353-367.	1.3	81
154	Etiologies of Extreme Thrombocytosis: A Contemporary Series. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1542-1550.	1.4	6
155	Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. <i>British Journal of Haematology</i> , 2019, 187, 588-594.	1.2	40
156	Postsurgical thrombotic microangiopathy: Case series and review of the literature. <i>European Journal of Haematology</i> , 2019, 103, 307-318.	1.1	7
157	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 101-102.	1.4	9
158	Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis. <i>Blood Advances</i> , 2019, 3, 1226-1229.	2.5	7
159	Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis. <i>Cancer</i> , 2019, 125, 3574-3581.	2.0	7
160	Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1467-1474.	1.4	12
161	Concomitant Erdheim-Chester disease and chronic myelomonocytic leukaemia: genomic insights into a common clonal origin. <i>British Journal of Haematology</i> , 2019, 187, e51-e54.	1.2	13
162	The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2054-2071.	1.4	116

#	ARTICLE	IF	CITATIONS
163	Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms. <i>Blood</i> , 2019, 133, 1607-1610.	0.6	23
164	Comparative analysis of staging systems in AL amyloidosis. <i>Leukemia</i> , 2019, 33, 811-814.	3.3	22
165	Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2960-2967.	0.6	4
166	Incidence, Clinical Features, and Outcomes of Langerhans Cell Sarcoma in the United States. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 441-446.	0.2	9
167	Cardiac prostheses-related hemolytic anemia. <i>Clinical Cardiology</i> , 2019, 42, 692-700.	0.7	24
168	Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1432-1438.	0.5	63
169	Natural history of multiple myeloma with de novo del(17p). <i>Blood Cancer Journal</i> , 2019, 9, 32.	2.8	38
170	Patterns and utility of vitamin B12 and folate testing in patients with isolated thrombocytopenia. <i>Annals of Hematology</i> , 2019, 98, 1993-1994.	0.8	2
171	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. <i>American Journal of Hematology</i> , 2019, 94, 751-756.	2.0	15
172	Substratification of patients with newly diagnosed standard-risk multiple myeloma. <i>British Journal of Haematology</i> , 2019, 185, 254-260.	1.2	12
173	Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. <i>Leukemia</i> , 2019, 33, 1268-1272.	3.3	7
174	Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. <i>Leukemia</i> , 2019, 33, 1273-1277.	3.3	12
175	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. <i>Mayo Clinic Proceedings</i> , 2019, 94, 472-483.	1.4	59
176	Impact of acquired del(17p) in multiple myeloma. <i>Blood Advances</i> , 2019, 3, 1930-1938.	2.5	41
177	Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. <i>Blood Advances</i> , 2019, 3, 744-750.	2.5	28
178	Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials. <i>Oncologist</i> , 2019, 24, 96-102.	1.9	35
179	Biosimilar Filgrastim Uptake And Costs Among Commercially Insured, Medicare Advantage. <i>Health Affairs</i> , 2019, 38, 1887-1892.	2.5	14
180	Venetoclax For The Treatment of Translocation AL Amyloidosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e332.	0.2	1

#	ARTICLE	IF	CITATIONS
181	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multiparametric flow cytometry method. <i>American Journal of Hematology</i> , 2019, 94, 424-430.	2.0	11
182	Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. <i>Leukemia</i> , 2019, 33, 790-794.	3.3	28
183	Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. <i>Leukemia</i> , 2019, 33, 730-738.	3.3	20
184	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. <i>Leukemia</i> , 2019, 33, 527-531.	3.3	36
185	Prevalence and survival of smouldering Waldenström macroglobulinaemia in the United States. <i>British Journal of Haematology</i> , 2019, 184, 1014-1017.	1.2	20
186	Glycosylation of Immunoglobulin Light Chains Is Highly Prevalent in Cold Agglutinin Disease. <i>Blood</i> , 2019, 134, 3510-3510.	0.6	1
187	Single-Agent Cladribine As an Effective Therapy for Adults with Langerhans Cell Histiocytosis. <i>Blood</i> , 2019, 134, 4189-4189.	0.6	2
188	Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , 2019, 134, 72-72.	0.6	2
189	Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. <i>Blood</i> , 2019, 134, 4334-4334.	0.6	1
190	Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma. <i>Blood</i> , 2019, 134, 4386-4386.	0.6	2
191	Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma. <i>Blood</i> , 2019, 134, 1905-1905.	0.6	2
192	Adult Langerhans cell histiocytosis: A contemporary single-institution series of 186 patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7018-7018.	0.8	9
193	OR32-1 Endocrine Manifestations of Erdheim-Chester Disease: The Mayo Clinic Experience. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	2
194	PS1397 OUTCOMES OF LONG-TERM SURVIVORS WITH ACTIVE MULTIPLE MYELOMA. <i>HemaSphere</i> , 2019, 3, 641-641.	1.2	0
195	Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations. <i>Blood</i> , 2019, 134, 90-90.	0.6	2
196	Clinical Features and Outcomes of Unifocal Adult Langerhans Cell Histiocytosis. <i>Blood</i> , 2019, 134, 1667-1667.	0.6	2
197	Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14). <i>Blood</i> , 2019, 134, 5523-5523.	0.6	0
198	Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. <i>Blood</i> , 2019, 134, 1532-1532.	0.6	0

#	ARTICLE	IF	CITATIONS
199	Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 4396-4396.	0.6	0
200	Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition. <i>Blood</i> , 2019, 134, 3080-3080.	0.6	0
201	Molecular Alterations in Adult Histiocytic Neoplasms. <i>Blood</i> , 2019, 134, 2975-2975.	0.6	2
202	Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 5833-5833.	0.6	0
203	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma. <i>Blood</i> , 2019, 134, 1904-1904.	0.6	0
204	Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis. <i>Blood</i> , 2019, 134, 5532-5532.	0.6	0
205	Sex Differences in Faculty Rank and Leadership Positions Amongst Hematologists and Oncologists in United States: A Cross-Sectional Study. <i>Blood</i> , 2019, 134, 3399-3399.	0.6	0
206	Desideromastica: Tactile Chew Cravings in Iron Deficiency Anemia. <i>Blood</i> , 2019, 134, 4815-4815.	0.6	0
207	Low-Dose BRAF-Inhibitors in the Treatment of Histiocytic Disorders with the BRAF-V600E Mutation. <i>Blood</i> , 2019, 134, 5895-5895.	0.6	2
208	A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. <i>Blood</i> , 2019, 134, 1800-1800.	0.6	1
209	Use of Imaging During Staging and Surveillance of Localized Colon Cancer in a Large Insured Population. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1355-1361.	2.3	2
210	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 2197-2197.	0.6	0
211	Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. <i>Blood</i> , 2019, 134, 5490-5490.	0.6	1
212	African American Race Is Associated with Decreased Relapse-Free Survival in Immune Thrombotic Thrombocytopenic Purpura. <i>Blood</i> , 2019, 134, 1066-1066.	0.6	2
213	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. <i>Leukemia</i> , 2018, 32, 1421-1426.	3.3	8
214	Approach to pancytopenia: Diagnostic algorithm for clinical hematologists. <i>Blood Reviews</i> , 2018, 32, 361-367.	2.8	35
215	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. <i>Leukemia</i> , 2018, 32, 2240-2249.	3.3	64
216	Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 889-894.	2.0	14

#	ARTICLE	IF	CITATIONS
217	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. <i>Annals of Hematology</i> , 2018, 97, 1417-1425.	0.8	71
218	Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset. <i>Leukemia</i> , 2018, 32, 1414-1420.	3.3	20
219	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. <i>Leukemia</i> , 2018, 32, 1811-1815.	3.3	28
220	Letter to the Editor: Chicken Noodle Soup (Capsule) for the Soul?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 108-109.	2.3	0
221	Neuroradiologic manifestations of Erdheim-Chester disease. <i>Neurology: Clinical Practice</i> , 2018, 8, 15-20.	0.8	43
222	Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2018, 53, 326-333.	1.3	4
223	Risk of progression of monoclonal gammopathy of undetermined significance into lymphoplasmacytic malignancies: determining demographic differences in the USA. <i>Haematologica</i> , 2018, 103, e123-e125.	1.7	7
224	Adult disseminated Langerhans cell histiocytosis: incidence, racial disparities and long-term outcomes. <i>British Journal of Haematology</i> , 2018, 182, 579-581.	1.2	43
225	Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 179-186.	2.0	49
226	MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 187-194.	2.0	57
227	Efficacy of biological agents in the treatment of Erdheim-Chester disease. <i>British Journal of Haematology</i> , 2018, 183, 520-524.	1.2	24
228	Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). <i>American Journal of Hematology</i> , 2018, 93, 17-22.	2.0	11
229	How I manage monoclonal gammopathy of undetermined significance. <i>Blood</i> , 2018, 131, 163-173.	0.6	88
230	Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes. <i>Blood</i> , 2018, 131, 265-268.	0.6	73
231	¹⁸ F-FDG PET/CT in Erdheim-Chester Disease: Imaging Findings and Potential BRAF Mutation Biomarker. <i>Journal of Nuclear Medicine</i> , 2018, 59, 774-779.	2.8	46
232	Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years. <i>Journal of Oncology Practice</i> , 2018, 14, e1-e10.	2.5	245
233	Reply to E.L. Pollom et al, N. Ohri et al, A. Fiorentino et al, D.R. Wahl et al, N. Kim et al, J. Boda-Heggemann et al, S. Rana et al, N. Sanuki et al, J.R. Olsen et al, G.L. Smith et al, and A. Shinde et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 2567-2569.	0.8	2
234	Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database. <i>Journal of Clinical Oncology</i> , 2018, 36, 600-608.	0.8	160

#	ARTICLE	IF	CITATIONS
235	Commentary: Race and Ethnicity in Biomedical Research â€“ Classifications, Challenges, and Future Directions. <i>Ethnicity and Disease</i> , 2018, 28, 561-564.	1.0	19
236	Arterial involvement in Erdheimâ€“Chester disease. <i>Medicine (United States)</i> , 2018, 97, e13452.	0.4	24
237	In Reply. <i>Oncologist</i> , 2018, 23, e163.	1.9	0
238	Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 116.	2.8	64
239	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. <i>Blood Cancer Journal</i> , 2018, 8, 125.	2.8	29
240	Pompe Disease Could Mimic Exam Findings of Amyloidosis: Two Rare Diagnoses Bona Fide. <i>Case Reports in Hematology</i> , 2018, 2018, 1-4.	0.3	1
241	Diagnostic Utility of Complement Serology for Atypical Hemolytic Uremic Syndrome. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1351-1362.	1.4	17
242	Utility and prognostic value of ¹⁸ Fâ€“FDG positron emission tomographyâ€“computed tomography scans in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 1518-1523.	2.0	19
243	Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. <i>Blood Advances</i> , 2018, 2, 3149-3154.	2.5	23
244	Florid dermatopathic lymphadenopathy-A morphological mimic of Langerhans cell histiocytosis. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 1637-1638.	0.2	6
245	Mixed-phenotype large granular lymphocytic leukemia: a rare subtype in the large granular lymphocytic leukemia spectrum. <i>Human Pathology</i> , 2018, 81, 96-104.	1.1	9
246	Representation of Minorities and Elderly Patients in Multiple Myeloma Clinical Trials. <i>Oncologist</i> , 2018, 23, 1076-1078.	1.9	37
247	Association between hospital volume and mortality of patients with metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 122, 214-219.	0.9	22
248	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 70.	2.8	18
249	Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management. <i>Journal of Immunological Methods</i> , 2018, 461, 15-22.	0.6	34
250	Predicting Time to First Treatment in Chronic Lymphocytic Leukemia Using Machine Learning Survival and Classification Methods. , 2018, , .		4
251	Shiga Toxin as a Potential Trigger of CFHR1 Deletion-Associated Thrombotic Microangiopathy. <i>American Journal of the Medical Sciences</i> , 2018, 356, 492-498.	0.4	3
252	Serum free light chain measurements to reduce 24â€“h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. <i>American Journal of Hematology</i> , 2018, 93, 1207-1210.	2.0	3

#	ARTICLE	IF	CITATIONS
253	Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e006588.	1.3	51
254	Incidence and Mortality Outcomes in Allogeneic Transplant-Associated Thrombotic Microangiopathy. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S329-S330.	2.0	3
255	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 1384-1393.	2.0	24
256	Evaluation of thrombocytopenia in the hematology clinic: a case series from a large tertiary care center. <i>Blood Research</i> , 2018, 53, 166.	0.5	0
257	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. <i>Blood Cancer Journal</i> , 2018, 8, 59.	2.8	171
258	Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018, 132, 304-304.	0.6	10
259	Immune-Mediated Hematologic Complications of Checkpoint Inhibitors: A Review of the Literature. <i>Blood</i> , 2018, 132, 5883-5883.	0.6	1
260	Changes in Imaging Surveillance of Diffuse Large B-Cell Lymphoma Survivors after Publication of the American Society of Hematology Choosing Wisely® Recommendations. <i>Blood</i> , 2018, 132, 618-618.	0.6	1
261	Prognostic Value of Clone Size in Paroxysmal Nocturnal Hemoglobinuria (PNH) for Thrombotic Events in Untreated Patients in the International PNH Registry. <i>Blood</i> , 2018, 132, 1038-1038.	0.6	0
262	Long-Term Survivorship with Active Multiple Myeloma. <i>Blood</i> , 2018, 132, 1912-1912.	0.6	0
263	Comparative Analysis of Staging Systems in AL Amyloidosis. <i>Blood</i> , 2018, 132, 3228-3228.	0.6	0
264	Treatment Facility Volume and Outcomes in Waldenström Macroglobulinemia. <i>Blood</i> , 2018, 132, 622-622.	0.6	1
265	Trends in Multiple Myeloma Incidence in the United States (US): Demographic and Geographic Considerations and Focus on Young Adults. <i>Blood</i> , 2018, 132, 5575-5575.	0.6	3
266	Depth of Response in Waldenström Macroglobulinemia. <i>Blood</i> , 2018, 132, 4141-4141.	0.6	2
267	Early Prediction of Treatment Response in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018, 132, 3159-3159.	0.6	0
268	Comparison of Different Techniques to Identify Cardiac Involvement in Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2018, 132, 3182-3182.	0.6	0
269	Prognostic Significance of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018, 132, 3158-3158.	0.6	0
270	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. <i>Blood</i> , 2018, 132, 4449-4449.	0.6	0

#	ARTICLE	IF	CITATIONS
271	Confirming the Presence of a Smoldering T and B PLL Associated with Improved 5 Year OS: Using the National Cancer Data Base. <i>Blood</i> , 2018, 132, 5543-5543.	0.6	1
272	Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. <i>Blood</i> , 2018, 132, 3226-3226.	0.6	0
273	Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma. <i>Blood</i> , 2018, 132, 4497-4497.	0.6	0
274	Mass Spectrometry to Measure Response in Immunoglobulin Light Chain Amyloidosis (AL). <i>Blood</i> , 2018, 132, 4502-4502.	0.6	0
275	Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018, 132, 1902-1902.	0.6	1
276	Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis. <i>Blood</i> , 2018, 132, 5594-5594.	0.6	0
277	Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. <i>Blood</i> , 2018, 132, 3227-3227.	0.6	0
278	Clinical Associations, Treatment, and Outcomes of Renal-Limited Thrombotic Microangiopathy. <i>Blood</i> , 2018, 132, 4978-4978.	0.6	4
279	Characterization of Exceptional Responders to Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2018, 132, 4615-4615.	0.6	0
280	Frequency of Acquired Genetic Mutations and Their Prognostic Impact on Patients with Incidental Finding of Isolated 20q- in Bone Marrow without Morphologic Evidence of a Myeloid Neoplasm. <i>Blood</i> , 2018, 132, 4382-4382.	0.6	0
281	Tumor Mutational Burden and Other Immunotherapy Markers in Histiocytic Neoplasms Using Next Generation Sequencing. <i>Blood</i> , 2018, 132, 1112-1112.	0.6	1
282	Incidence, Clinical Features, and Outcomes of Langerhans Cell Sarcoma in the United States. <i>Blood</i> , 2018, 132, 3031-3031.	0.6	0
283	Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. <i>Blood</i> , 2018, 132, 3160-3160.	0.6	2
284	Association between Treatment Facility Volume and Mortality of Patients with Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 2257-2257.	0.6	0
285	Prognosis of Patients with Waldenström Macroglobulinemia: A Simplified Model. <i>Blood</i> , 2018, 132, 4152-4152.	0.6	1
286	Monoclonal Gammopathy of Undetermined Significance (MGUS): Indications for Pre-Diagnostic Testing, Subsequent Diagnoses, and Follow-up Practice. <i>Blood</i> , 2018, 132, 2224-2224.	0.6	0
287	Patient-Reported Outcome Driven Case Management System for Hematology – a Prospective Study. <i>Blood</i> , 2018, 132, 719-719.	0.6	1
288	Immune-mediated hemolytic anemia and thrombocytopenia in clonal B-cell disorders: a review. <i>Clinical Advances in Hematology and Oncology</i> , 2018, 16, 670-676.	0.3	7

#	ARTICLE	IF	CITATIONS
289	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. <i>Leukemia</i> , 2017, 31, 92-99.	3.3	30
290	Estimating the annual volume of hematologic cancer cases per hematologist- <i>oncologist</i> in the United States: are we treating rare cancers too rarely?. <i>Leukemia and Lymphoma</i> , 2017, 58, 251-252.	0.6	6
291	Association Between Treatment Facility Volume and Mortality of Patients With Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2017, 35, 598-604.	0.8	58
292	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. <i>Annals of Medicine</i> , 2017, 49, 545-551.	1.5	45
293	<i>Desiderosmia</i> (olfactory craving): A novel symptom associated with iron deficiency anemia. <i>American Journal of Hematology</i> , 2017, 92, E93-E94.	2.0	5
294	Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease. <i>JAMA Oncology</i> , 2017, 3, 1253.	3.4	47
295	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. <i>American Journal of Hematology</i> , 2017, 92, 435-440.	2.0	16
296	Incidence, clinical findings, and survival of hepatosplenic <i>T</i> -cell lymphoma in the United States. <i>American Journal of Hematology</i> , 2017, 92, E99-E101.	2.0	17
297	The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. <i>Blood</i> , 2017, 129, 82-87.	0.6	50
298	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. <i>Blood</i> , 2017, 129, 2111-2119.	0.6	249
299	High prevalence of monoclonal gammopathy among patients with warm autoimmune hemolytic anemia. <i>American Journal of Hematology</i> , 2017, 92, E164-E166.	2.0	5
300	Feeling run down: exercise-induced pancytopenia. <i>British Journal of Haematology</i> , 2017, 177, 672-672.	1.2	2
301	The impact of postpartum hemorrhage on hospital length of stay and inpatient mortality: a National Inpatient Sample-based analysis. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 344.e1-344.e6.	0.7	71
302	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 40-41.	1.4	4
303	Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 44-45.	1.4	1
304	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. <i>American Journal of Hematology</i> , 2017, 92, E507-E512.	2.0	5
305	Sex-based disparities in venous thromboembolism outcomes: A National Inpatient Sample (NIS)-based analysis. <i>Vascular Medicine</i> , 2017, 22, 121-127.	0.8	18
306	Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. <i>American Journal of Hematology</i> , 2017, 92, 668-673.	2.0	75

#	ARTICLE	IF	CITATIONS
307	How I treat autoimmune hemolytic anemia. <i>Blood</i> , 2017, 129, 2971-2979.	0.6	134
308	Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. <i>American Journal of Hematology</i> , 2017, 92, 549-554.	2.0	24
309	Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 48.	3.8	253
310	Diagnosis and Management of Waldenström Macroglobulinemia. <i>JAMA Oncology</i> , 2017, 3, 1257.	3.4	110
311	Thrombotic microangiopathy associated with monoclonal gammopathy. <i>Kidney International</i> , 2017, 91, 691-698.	2.6	78
312	Treatment Patterns and Outcomes in Early-stage Hodgkin Lymphoma in the Elderly: A National Cancer Database Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 812-818.	0.2	8
313	Delineation of the timing of second-line therapy post autologous stem cell transplant in patients with AL amyloidosis. <i>Blood</i> , 2017, 130, 1578-1584.	0.6	21
314	In-Hospital Outcomes of Tumor Lysis Syndrome: A Population-Based Study Using the National Inpatient Sample. <i>Oncologist</i> , 2017, 22, 1506-1509.	1.9	41
315	Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. <i>British Journal of Haematology</i> , 2017, 178, 888-895.	1.2	15
316	The Authors Reply. <i>Kidney International</i> , 2017, 92, 517.	2.6	0
317	Bortezomib Versus Non-Bortezomib Based Initial Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e140-e141.	0.2	0
318	LOW GRADE B-CELL NON-HODGKIN LYMPHOMAS INVOLVING THE CENTRAL NERVOUS SYSTEM: AN ANALYSIS FROM THE NATIONAL CANCER DATABASE. <i>Hematological Oncology</i> , 2017, 35, 224-225.	0.8	0
319	Pseudo-monoclonal gammopathy: a report of four cases. <i>Haematologica</i> , 2017, 102, e466-e469.	1.7	11
320	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenström macroglobulinemia. <i>British Journal of Haematology</i> , 2017, 179, 98-105.	1.2	25
321	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. <i>American Journal of Hematology</i> , 2017, 92, 1146-1155.	2.0	25
322	Clinical and radiological responses to oral methotrexate alone or in combination with other agents in Erdheim-Chester disease. <i>Blood Cancer Journal</i> , 2017, 7, 647.	2.8	8
323	Monoclonal Gammopathy of Undetermined Significance. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2017, 1, 161-169.	1.2	8
324	Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 183-188.	1.4	4

#	ARTICLE	IF	CITATIONS
325	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. <i>Blood</i> , 2017, 130, 1198-1204.	0.6	54
326	Racial and ethnic disparities in the survival of adolescents and young adults with acute myeloid leukemia: a retrospective study using the US National Cancer Data Base. <i>Leukemia and Lymphoma</i> , 2017, 58, 1184-1189.	0.6	5
327	Natural history of amyloidosis isolated to fat and bone marrow aspirate. <i>British Journal of Haematology</i> , 2017, 179, 170-172.	1.2	10
328	Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. <i>American Journal of Hematology</i> , 2017, 92, 50-55.	2.0	41
329	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2017, 92, 908-917.	1.4	72
330	A follow-up on desiderosmia (olfactory craving), a novel symptom associated with iron deficiency anemia. <i>American Journal of Hematology</i> , 2017, 92, E546.	2.0	5
331	Daratumumab-based combination therapies (DCT) in heavily-pretreated patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8038-8038.	0.8	1
332	Factors predicting organ response in light chain amyloidosis (AL).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8048-8048.	0.8	1
333	Association between hospital volume and overall survival of patients with metastatic non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9044-9044.	0.8	1
334	Low grade b-cell non-Hodgkin lymphomas (NHL) involving the central nervous system (CNS): An analysis from the National Cancer Database (NCDB).. <i>Journal of Clinical Oncology</i> , 2017, 35, e13083-e13083.	0.8	3
335	Natural history of t(11;14) multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8014-8014.	0.8	1
336	The use of proteasome inhibitors among patients with POEMS syndrome.. <i>Journal of Clinical Oncology</i> , 2017, 35, e19530-e19530.	0.8	0
337	Outcomes according to involved free light chain (FLC) levels in patients with normal FLC ratio after initial therapy in light chain amyloidosis (AL).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8049-8049.	0.8	0
338	Risk stratification by detection of clonal circulating plasma cells (CPCs) by multi-parametric flow cytometry (MFC) in light chain amyloidosis (AL).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8047-8047.	0.8	0
339	Overuse of organ biopsies in immunoglobulin light chain (AL) amyloidosis: The consequence of failure of early recognition.. <i>Journal of Clinical Oncology</i> , 2017, 35, e19532-e19532.	0.8	0
340	Smoldering Waldenström's macroglobulinemia (SWM): Analysis from the National Cancer Database (NCDB).. <i>Journal of Clinical Oncology</i> , 2017, 35, 1573-1573.	0.8	0
341	In-hospital outcomes of acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic stem cell transplant (HCT).. <i>Journal of Clinical Oncology</i> , 2017, 35, e18091-e18091.	0.8	0
342	The impact of body mass index on the risk of early progression of smoldering multiple myeloma to symptomatic myeloma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8032-8032.	0.8	0

#	ARTICLE	IF	CITATIONS
343	Clinical and Serological Characteristics of Cold Autoimmune Hemolytic Anemia with Concomitant Cold Agglutinin and Donath-Landsteiner Antibodies. <i>Blood</i> , 2017, 130, 927-927.	0.6	0
344	Autoimmune Hemolytic Anemia in Children. <i>Journal of Pediatric Hematology/Oncology</i> , 2016, 38, e120-e124.	0.3	33
345	Clinical course of patients with incidental finding of 20qâ€”in the bone marrow without a morphologic evidence of myeloid neoplasm. <i>American Journal of Hematology</i> , 2016, 91, 556-559.	2.0	9
346	Bendamustine+Â”rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: AÂ”Wisconsin Oncology Network Study. <i>British Journal of Haematology</i> , 2016, 173, 283-291.	1.2	13
347	Induction therapy preâ€”autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. <i>American Journal of Hematology</i> , 2016, 91, 984-988.	2.0	45
348	Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. <i>Blood</i> , 2016, 128, 2415-2422.	0.6	51
349	Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. <i>Blood Cancer Journal</i> , 2016, 6, e454-e454.	2.8	56
350	Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. <i>Haematologica</i> , 2016, 101, 1102-1109.	1.7	9
351	Pulmonary Presentation Without Concurrent Bone Involvement in Erdheim-Chester Disease: A Report of Two Cases. <i>Chest</i> , 2016, 150, 1090A.	0.4	0
352	Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 447-452.	0.2	24
353	Exploring Big Data in Hematological Malignancies: Challenges and Opportunities. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 271-279.	1.2	3
354	Polyclonal Localized Light Chain Amyloidosisâ€”A Distinct Entity?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 588-592.	0.2	7
355	Myelomatous Involvement of the Central Nervous System. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 644-654.	0.2	38
356	Systemic Immunoglobulin Light Chain Amyloidosisâ€”Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1354-1361.	1.4	43
357	61-Year-Old Man With Right Knee Pain and Chronic Anemia. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1640-1644.	1.4	0
358	Longâ€”term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. <i>American Journal of Hematology</i> , 2016, 91, 585-589.	2.0	57
359	Transient monosomy 7 in a chronic myelogenous leukemia patient during nilotinib therapy: a case report. <i>Clinical Case Reports (discontinued)</i> , 2016, 4, 282-286.	0.2	8
360	Enteropathyâ€”Associated Tâ€”cell lymphoma in the US: higher incidence and poorer survival among Asians. <i>British Journal of Haematology</i> , 2016, 172, 990-992.	1.2	6

#	ARTICLE	IF	CITATIONS
361	21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013. <i>Breast Cancer Research and Treatment</i> , 2016, 159, 315-326.	1.1	18
362	N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2016, 91, 1129-1134.	2.0	71
363	Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1189-1211.	1.4	55
364	Clinical Features and Outcomes of Plasmacytoma: a National Cancer Database Study (2000 - 2011). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S81-S82.	0.2	0
365	Increased Multinucleated Megakaryocytes as an Isolated Finding in Bone Marrow. <i>American Journal of Clinical Pathology</i> , 2016, 146, 561-566.	0.4	4
366	Langerhans Cell Histiocytosis and Other Histiocytic Diseases of the Lung. <i>Clinics in Chest Medicine</i> , 2016, 37, 421-430.	0.8	25
367	Influence of the treatment facility volume on the survival of patients with non-Hodgkin lymphoma. <i>Cancer</i> , 2016, 122, 2552-2559.	2.0	22
368	Clinical characteristics and outcomes in biclonal gammopathies. <i>American Journal of Hematology</i> , 2016, 91, 473-475.	2.0	30
369	Outcome of Whole Exome Sequencing for Diagnostic Odyssey Cases of an Individualized Medicine Clinic. <i>Mayo Clinic Proceedings</i> , 2016, 91, 297-307.	1.4	83
370	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1284-1289.	0.4	25
371	Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 2082-2082.	0.6	1
372	Characteristics and Outcome of Direct Antiglobulin Test-Negative Hemolytic Anemia: A Case Series. <i>Blood</i> , 2016, 128, 2451-2451.	0.6	1
373	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). <i>Blood</i> , 2016, 128, 2968-2968.	0.6	4
374	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. <i>Blood</i> , 2016, 128, 2972-2972.	0.6	2
375	Clinical Features and Outcomes of Plasmacytoma in the United States: Analysis Using the National Cancer Data Base. <i>Blood</i> , 2016, 128, 3249-3249.	0.6	1
376	Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis. <i>Blood</i> , 2016, 128, 3272-3272.	0.6	1
377	Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 3317-3317.	0.6	3
378	Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting. <i>Blood</i> , 2016, 128, 3337-3337.	0.6	5

#	ARTICLE	IF	CITATIONS
379	Practice Patterns of Re-Initiation of Therapy at Time of Relapse or Progression Post- Autologous Stem Cell Transplant (ASCT) Among Patients with AL Amyloidosis. <i>Blood</i> , 2016, 128, 3444-3444.	0.6	1
380	Outcome of Myelodysplastic Syndromes over Time in the US: A National Cancer Data Base Study from 2004-2013. <i>Blood</i> , 2016, 128, 3604-3604.	0.6	3
381	Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage. <i>Blood</i> , 2016, 128, 4627-4627.	0.6	1
382	Blastic Plasmacytoid Dendritic Cell Neoplasm. a Population-Based Analysis from the SEER and NCDB Databases. <i>Blood</i> , 2016, 128, 4789-4789.	0.6	6
383	Estimating the Risk of Progression of Monoclonal Gammopathy of Undetermined Significance into Lymphoplasmacytic Malignancies in the United States: Determining Demographic Differences Using a National Dataset. <i>Blood</i> , 2016, 128, 843-843.	0.6	7
384	Phase 1/2 trial of ixazomib, cyclophosphamide, and dexamethasone for newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8002-8002.	0.8	5
385	Evolving changes in M-protein (M), quantitative involved immunoglobulin (Ig), and hemoglobin (Hb) to identify patients (pts) with ultra high-risk smoldering multiple myeloma (UHR-SMM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8004-8004.	0.8	3
386	Quantification of circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC) to identify patients with smoldering multiple myeloma (SMM) at high risk of progression.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8015-8015.	0.8	1
387	NK/T cell lymphoma in the U.S: A population-based study using the National Cancer Database from 1998-2012.. <i>Journal of Clinical Oncology</i> , 2016, 34, e19038-e19038.	0.8	6
388	Racial and ethnic disparities in the survival of adolescents and young adults (AYA) with acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2016, 34, 297-297.	0.8	1
389	The influence of treatment facility volume on the mortality of multiple myeloma patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 284-284.	0.8	1
390	Disparity in early mortality among racial groups with multiple myeloma in the United States: A National Cancer Data Base study of 108,352 patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 311-311.	0.8	1
391	In-hospital outcomes of tumor lysis syndrome: A population-based study using the National Inpatient Sample (NIS).. <i>Journal of Clinical Oncology</i> , 2016, 34, 6582-6582.	0.8	0
392	Changes in serum alkaline phosphatase levels to predict response to ixazomib-based therapy in patients with newly diagnosed multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8053-8053.	0.8	0
393	Clinical utility of the revised international staging system (RISS) in newly diagnosed multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8017-8017.	0.8	0
394	Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment naïve (TN) Waldenström macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7552-7552.	0.8	1
395	Treatment trends and outcomes in early-stage Hodgkin lymphoma in elderly: A National Cancer Data Base analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7536-7536.	0.8	0
396	Immunoparesis in newly diagnosed AL amyloidosis as a marker for response and survival.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8016-8016.	0.8	0

#	ARTICLE	IF	CITATIONS
397	Desiderosmia (Craving of Olfaction): A Novel Symptom Associated with Iron Deficiency Anemia. Blood, 2016, 128, 4827-4827.	0.6	0
398	Clinical Presentation and Outcome of Patients with Myeloid Differentiation Factor 88 Gene (MYD88) Wild-Type Waldenstrom Macroglobulinemia. Blood, 2016, 128, 2960-2960.	0.6	15
399	In-Hospital Outcomes of Neutropenic Fever: A Study Using the National Inpatient Sample, Years 2009-2013. Blood, 2016, 128, 4762-4762.	0.6	0
400	Significant Variability in the Initial Workup of Thrombocytopenia in the Hematology Clinic - What Is the "Optimal" Workup?. Blood, 2016, 128, 5966-5966.	0.6	0
401	Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2016, 128, 5615-5615.	0.6	0
402	Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. Blood, 2016, 128, 3273-3273.	0.6	0
403	Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy. Blood, 2016, 128, 3251-3251.	0.6	0
404	Clinical Features and Outcomes of Isolated Myeloid Sarcoma in the United States: Analysis Using a National Dataset. Blood, 2016, 128, 1618-1618.	0.6	2
405	Monoclonal Gammopathy of Undetermined Significance (MGUS) Follow-up Practice Patterns in the US: Frequency of Visits, Types of Tests and Concordance with Clinical Practice Guidelines. Blood, 2016, 128, 5906-5906.	0.6	1
406	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. Blood, 2016, 128, 1810-1810.	0.6	0
407	Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation. Blood, 2016, 128, 3306-3306.	0.6	0
408	The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. Blood, 2016, 128, 1194-1194.	0.6	0
409	Sex-Based Disparities in Venous Thromboembolism Sociodemographics and Outcomes: A National Inpatient Sample (NIS)-Based Analysis. Blood, 2016, 128, 5918-5918.	0.6	1
410	Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. Blood, 2016, 128, 3269-3269.	0.6	0
411	Disparities in the Upfront Use of Hematopoietic Stem Cell Transplant Among Patients with Acute Myeloid Leukemia. Blood, 2016, 128, 3543-3543.	0.6	0
412	Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis. Blood, 2016, 128, 3338-3338.	0.6	0
413	Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents. Blood, 2016, 128, 3255-3255.	0.6	0
414	Characterizing the Use of Gastrointestinal Procedures in the Workup of Anemia: Patterns of Care and Areas for Improvement. Blood, 2016, 128, 4748-4748.	0.6	0

#	ARTICLE	IF	CITATIONS
415	Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 2187-2187.	0.6	0
416	Clinical and Biological significance of MYC/BCL6 dual gene rearrangements and protein co-expression in de novo diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S228.	0.2	0
417	Institutional Review of Compliance With NCCN Guidelines for Breast Cancer: Lessons Learned From Real-Time Multidimensional Synoptic Reporting. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 177-183.	2.3	15
418	Speed of Accrual Into Phase III Oncology Trials. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 575-582.	0.6	3
419	Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. <i>American Journal of Hematology</i> , 2015, 90, 888-891.	2.0	18
420	Outcomes of primary refractory multiple myeloma and the impact of novel therapies. <i>American Journal of Hematology</i> , 2015, 90, 981-985.	2.0	38
421	Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the United States: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011. <i>American Journal of Hematology</i> , 2015, 90, 790-795.	2.0	221
422	Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. <i>American Journal of Hematology</i> , 2015, 90, 181-186.	2.0	76
423	Determining the Clinical Significance of Monoclonal Gammopathy of Undetermined Significance: A SEER Medicare Population Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 177-186.e4.	0.2	52
424	Treatment of Immunoglobulin Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1054-1081.	1.4	106
425	Stage redistribution and survival among Medicare beneficiaries before and after the approval of positron emission tomography scan for non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1544-1546.	0.6	2
426	Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. <i>American Journal of Hematology</i> , 2015, 90, 524-528.	2.0	31
427	A simple model to predict survival using age, comorbidities and functional status in patients with multiple myeloma (MM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e94-e95.	0.2	0
428	Erdheim-Chester Disease. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1310.	1.4	5
429	Making the Case to Study the Volume-Outcome Relationship in Hematologic Cancers. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1393-1399.	1.4	11
430	The Reversal of Renal Impairment and its Impact on Survival in Newly Diagnosed Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S239.	0.2	0
431	Analysis of Serum Ferritin Levels As a Diagnostic Criteria for Hemophagocytic Lymphohistiocytosis (HLH) in Hospitalized Adult Patients. <i>Blood</i> , 2015, 126, 1014-1014.	0.6	3
432	Novel Genetic Variants in Complement-Mediated Thrombotic Microangiopath. <i>Blood</i> , 2015, 126, 1050-1050.	0.6	3

#	ARTICLE	IF	CITATIONS
433	In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO). Blood, 2015, 126, 1774-1774.	0.6	6
434	Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathies (MG): Clinical Features and Treatment Outcomes. Blood, 2015, 126, 1830-1830.	0.6	1
435	Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib. Blood, 2015, 126, 3050-3050.	0.6	8
436	Impact of Bone Marrow Plasmacytosis on Outcome in Patients with AL Amyloidosis Following Autologous Stem Cell Transplant. Blood, 2015, 126, 3177-3177.	0.6	3
437	Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. Blood, 2015, 126, 4197-4197.	0.6	5
438	Anaplastic Large Cell Lymphoma of the Breast: Incidence, Patterns of Care, and Outcome in the US Population. Blood, 2015, 126, 5035-5035.	0.6	1
439	Outcomes and treatment of patients with POEMS syndrome experiencing progression or relapse after first line treatment.. Journal of Clinical Oncology, 2015, 33, 8594-8594.	0.8	0
440	Early high-dose therapy and autologous stem-cell transplantation in angioimmunoblastic T-cell lymphoma: Outcome study using the National Cancer Data Base.. Journal of Clinical Oncology, 2015, 33, 8560-8560.	0.8	0
441	Clinical outcomes in t(11;14) multiple myeloma.. Journal of Clinical Oncology, 2015, 33, 8592-8592.	0.8	0
442	Survival trends in young patients with Waldenstrom macroglobulinemia (WM).. Journal of Clinical Oncology, 2015, 33, 8596-8596.	0.8	0
443	Estimating the Annual Volume of Hematologic Cancer Cases per Hematologist-Oncologist in the United States: Are We Treating Rare Cancers Too Rarely?. Blood, 2015, 126, 3297-3297.	0.6	0
444	A Population-Based Study of Large Granular Lymphocyte Leukemia: Analysis of 978 Patients Using the SEER and NCDB Databases. Blood, 2015, 126, 3302-3302.	0.6	0
445	Impact of the Type of Treatment Facility on the Outcome of Acute Myeloid Leukemia in the Adolescents and Young Adults: A National Cancer Data Base (NCDB) Study from 2003-2011. Blood, 2015, 126, 529-529.	0.6	0
446	Non-Hodgkin Lymphoma and American Indians/Alaska Natives: A SEER Population Study from 2000 to 2012. Blood, 2015, 126, 2110-2110.	0.6	5
447	N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM). Blood, 2015, 126, 3292-3292.	0.6	0
448	The Influence of Treatment Facility Volume on Survival of Non-Hodgkin Lymphoma: Determining the Volume-Outcome Relationship. Blood, 2015, 126, 266-266.	0.6	0
449	Large Deletions Involving the Beta Globin Gene Complex: Genotype-Phenotype Correlation of 119 Cases. Blood, 2015, 126, 3374-3374.	0.6	1
450	AL Amyloidosis and Patient Reported Quality of Life. Blood, 2015, 126, 3317-3317.	0.6	0

#	ARTICLE	IF	CITATIONS
451	Disparity in the Overall Survival Improvement over Time and the Effect Time-to-Treatment on the Outcome of Acute Promyelocytic Leukemia: A US National Cancer Data Base Study from 1998-2011. <i>Blood</i> , 2015, 126, 3747-3747.	0.6	0
452	Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma. <i>Blood</i> , 2015, 126, 4176-4176.	0.6	0
453	Natural History of Amyloidosis Isolated to Fat and Bone Marrow Aspirate. <i>Blood</i> , 2015, 126, 5303-5303.	0.6	0
454	Incidence and Outcomes of Neutropenia in Patients with Celiac Disease- a Consecutive Analysis of 1729 Patients. <i>Blood</i> , 2015, 126, 1013-1013.	0.6	0
455	Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 875-882.	1.1	31
456	Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute's Community Cancer Centers Program. <i>Cancer</i> , 2014, 120, 877-884.	2.0	97
457	Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy. <i>American Journal of Hematology</i> , 2014, 89, 302-305.	2.0	4
458	Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. <i>American Journal of Hematology</i> , 2014, 89, 1051-1054.	2.0	32
459	Phenotypic and Genotypic Profiling of MDM2, Respective to the TP53 Genetic Status, in Diffuse Large B-cell Lymphoma Patients Treated With Rituximab-CHOP Immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S146-S147.	0.2	0
460	Use of the National Cancer Institute Community Cancer Centers Program Screening and Accrual Log to Address Cancer Clinical Trial Accrual. <i>Journal of Oncology Practice</i> , 2014, 10, e73-e80.	2.5	42
461	Use of autologous hematopoietic cell transplantation as initial therapy in multiple myeloma and the impact of socio-demographic factors in the era of novel agents. <i>American Journal of Hematology</i> , 2014, 89, 825-830.	2.0	55
462	Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. <i>Blood</i> , 2014, 124, 907-912.	0.6	111
463	EBV-positive peripheral T-cell lymphoma with extensive hemophagocytosis. <i>Blood</i> , 2014, 124, 3329-3329.	0.6	3
464	Clinical Presentation, Diagnosis, Treatment, and Outcome of Patients with Erdheim-Chester Disease: The Mayo Clinic Experience. <i>Blood</i> , 2014, 124, 1405-1405.	0.6	5
465	NF- κ B Subunit c-Rel Cooperates with Myc and Mutated p53 to Confer Significantly Worse Survival in Patients with Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2014, 124, 1620-1620.	0.6	0
466	Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Lenalidomide Refractory Myeloma: Long Term Follow up and Comparison of 2 Mg Vs 4 Mg Doses. <i>Blood</i> , 2014, 124, 4780-4780.	0.6	0
467	Impact of Beta Blocker on Clinical Outcomes of Multiple Myeloma (MM) Patients. <i>Blood</i> , 2014, 124, 4751-4751.	0.6	0
468	Enteropathy-Associated T-Cell Lymphoma in the U.S.: A Population-Based Study Using Surveillance, Epidemiology, and End Results Program and National Cancer Data Base. <i>Blood</i> , 2014, 124, 1631-1631.	0.6	0

#	ARTICLE	IF	CITATIONS
469	Improvement in Renal Function and Its Impact on Survival in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2014, 124, 3368-3368.	0.6	1
470	Mutational Profile and Prognostic Significance of TP53 in Diffuse Large B-cell Lymphoma Patients Treated with Rituximab-CHOP: A Report From an International DLBCL Rituximab-CHOP Consortium Program Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, S382.	0.2	1
471	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 121, 4021-4031.	0.6	596
472	CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2013, 121, 2715-2724.	0.6	206
473	Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. <i>Haematologica</i> , 2013, 98, 255-263.	1.7	142
474	Early-Phase Clinical Trials In The Community: Results From the National Cancer Institute Community Cancer Centers Program Early-Phase Working Group Baseline Assessment. <i>Journal of Oncology Practice</i> , 2013, 9, e55-e61.	2.5	11
475	ECOG Phase II Trial of Graded-Dose Peginterferon α -2b in Patients with Metastatic Melanoma Overexpressing Basic Fibroblast Growth Factor (E2602). <i>Clinical Cancer Research</i> , 2013, 19, 6597-6604.	3.2	9
476	Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 121, 4529-4540.	0.6	41
477	Soluble ST2 (sST2) Is a Novel Valuable Prognostic Marker Among Patients With Immunoglobulin Light Chain (AL) Amyloidosis. <i>Blood</i> , 2013, 122, 3095-3095.	0.6	1
478	Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYC Translocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 122, 641-641.	0.6	3
479	Long-Term (10 Years or More) Survivors Of Multiple Myeloma: A Population-Based Analysis Of The US National Cancer Data Base. <i>Blood</i> , 2013, 122, 760-760.	0.6	1
480	Natural History Of Smoldering Monoclonal Gammopathy-Associated Malignancies: A Population-Based Study. <i>Blood</i> , 2013, 122, 5318-5318.	0.6	0
481	Effect Of Immediate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple Myeloma. <i>Blood</i> , 2013, 122, 1979-1979.	0.6	0
482	Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYC Translocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 122, 213-213.	0.6	0
483	Utility of Routine Left Ventricular Ejection Fraction Measurement Before Anthracycline-Based Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma. <i>Journal of Oncology Practice</i> , 2012, 8, 336-340.	2.5	18
484	Cancer in the oldest old in the United States: Current statistics and projections. <i>Journal of Geriatric Oncology</i> , 2012, 3, 299-306.	0.5	23
485	Angiogenic Blockade with Bevacizumab Does Not Increase Response to Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Myeloma. <i>Blood</i> , 2012, 120, 5041-5041.	0.6	3
486	Prognostic Significance and Phenotypic Manifestations of MYC/BCL2 Protein Expression in Diffuse Large B-Cell Lymphoma (DLBCL) with Extranodal Organ Involvement: A Report of the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2012, 120, 544-544.	0.6	1

#	ARTICLE	IF	CITATIONS
487	Utility of Routine Bone Marrow Fluorescent in Situ Hybridization (FISH) Panel Testing in Patients Suspected of Myelodysplastic Syndrome (MDS): An Analysis of 3,418 Patients and Comparison of Academic Versus Community Practices. <i>Blood</i> , 2012, 120, 3855-3855.	0.6	0
488	Cancer Complications At the Time of Multiple Myeloma Diagnosis and the Impact of Monoclonal Gammopathy of Undetermined Significance (MGUS) Follow-up: A Population-Based Study. <i>Blood</i> , 2012, 120, 3996-3996.	0.6	1
489	Floral variant of follicular lymphoma. <i>American Journal of Hematology</i> , 2011, 86, 503-503.	2.0	2
490	Proportions of bone marrow lymphocyte subsets at diagnosis may predict survival in patients with newly diagnosed diffuse large B-cell lymphoma independently of the international prognostic index. <i>American Journal of Hematology</i> , 2011, 86, 622-624.	2.0	0
491	Level of Scientific Evidence Underlying Recommendations Arising From the National Comprehensive Cancer Network Clinical Practice Guidelines. <i>Journal of Clinical Oncology</i> , 2011, 29, 186-191.	0.8	129
492	Prognostic Value of cMYC Gene Abnormalities in Diffuse Large B Cell Lymphoma Treated with Chemo-Immunotherapy. <i>Blood</i> , 2011, 118, 2664-2664.	0.6	2
493	The t(14;18)(q32;q21) Characterizes a Subset of Patients with Diffuse Large-B Cell Lymphoma of Germinal Center Origin with Poor Outcome: Report From the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2011, 118, 949-949.	0.6	3
494	Level of Scientific Evidence Underlying Recommendations Arising From the National Comprehensive Cancer Network Clinical Practice Guidelines for Hematologic Malignancies. <i>Blood</i> , 2011, 118, 509-509.	0.6	0
495	Risk of Second Cancers Among Multiple Myeloma (MM) Patients in the Era of Novel Agents: Analysis Using the Surveillance, Epidemiology and End Results (SEER) Database. <i>Blood</i> , 2011, 118, 1859-1859.	0.6	0
496	Monoclonal gammopathy of undetermined significance: to screen or not to screen for multiple myeloma?. <i>British Journal of Haematology</i> , 2010, 149, 620-621.	1.2	4
497	Primary Testicular Diffuse Large B-Cell Lymphoma: A Population-Based Study on the Incidence, Natural History, and Survival Comparison With Primary Nodal Counterpart Before and After the Introduction of Rituximab. <i>Journal of Clinical Oncology</i> , 2009, 27, 5227-5232.	0.8	124
498	Contralateral testicular relapse after prophylactic radiation in a patient with primary testicular diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2009, 83, 603-605.	1.1	9
499	Uncertainty and discordance in the staging and prognosis of diffuse large B-cell lymphoma with isolated bilateral testicular involvement. <i>American Journal of Hematology</i> , 2009, 84, 762-763.	2.0	6
500	Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. <i>British Journal of Haematology</i> , 2009, 144, 409-415.	1.2	150
501	Extent and Nature of Advertising in Leading Hematology-Oncology Journals. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 92-93.	0.6	2
502	Publication Outcomes of Phase II Oncology Clinical Trials. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 253-257.	0.6	22
503	Determining Why and Which Clinicians Order Serum Protein Electrophoresis (SPEP), Subsequent Diagnoses Based On Indications, and Clinical Significance of Routine Follow-up: a Study of Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).. <i>Blood</i> , 2009, 114, 4883-4883.	0.6	7
504	Clinical Impact of TP53 Gene Mutations in Diffuse Large B-Cell Lymphoma (DLBCL): An International DLBCL Rituxan-CHOP Consortium Program Study.. <i>Blood</i> , 2009, 114, 967-967.	0.6	1

#	ARTICLE	IF	CITATIONS
505	Circulating endothelial cells in patients with chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2008, 87, 369-373.	0.8	7
506	Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. <i>Lancet</i> , The, 2008, 371, 395-403.	6.3	784
507	Reconciling New Organ Donation Laws With Patient's Autonomy and Rights to Self-determination of End-of-Life Medical Care—Reply. <i>Mayo Clinic Proceedings</i> , 2008, 83, 506.	1.4	0
508	Issues Behind Disclosure of Conflicts of Interest. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 2120.	3.8	1
509	Proportions of Bone Marrow Lymphocyte Subsets Predict Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Independent of International Prognostic Index. <i>Blood</i> , 2008, 112, 2834-2834.	0.6	0
510	Significant Survival Disparity Between Chronic Lymphocytic Leukemia (CLL) and Stage IV Small Lymphocytic Lymphoma (SLL) Patients: Analysis Using the Surveillance, Epidemiology and End Results (SEER) Database. <i>Blood</i> , 2008, 112, 4171-4171.	0.6	0
511	Financial Conflicts of Interest Among ASCO Annual Meeting Abstract Authors, Speakers, and Planners. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1415-1416.	3.0	12
512	The association between platelet autoantibody specificity and response to intravenous immunoglobulin G in the treatment of patients with immune thrombocytopenia. <i>Haematologica</i> , 2007, 92, 283-284.	1.7	72
513	Poor access to clinical trials among newly diagnosed adult cancer patients in the community—1999–2004. <i>Community Oncology</i> , 2007, 4, 695-700.	0.2	1
514	Interstitial Lung Disease in Patients with Diffuse Large B-Cell Lymphoma Receiving CHOP-Based Chemotherapy Is Associated with the Use of Rituximab. <i>Blood</i> , 2007, 110, 3435-3435.	0.6	1
515	Assessment of Psychological Distress in Patients Suffering from Hematological Disorders. <i>Blood</i> , 2007, 110, 636-636.	0.6	9
516	Health-Related Quality of Life (HRQoL) in Patients (Pts) with Chronic Immune Thrombocytopenic Purpura (ITP): Results from Two Placebo-Controlled Phase 3 Studies of AMG 531. <i>Blood</i> , 2007, 110, 1314-1314.	0.6	1
517	Health-Related Quality of Life (HRQoL) in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): Interim Results from an Open-Label Study of AMG 531. <i>Blood</i> , 2007, 110, 1324-1324.	0.6	1
518	Pseudothrombocytopenia Associated With Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2006, 81, 869.	1.4	5
519	Circulating Endothelial Cells and Circulating Endothelial Progenitor Cells in Polycythemia Vera. <i>Blood</i> , 2006, 108, 4900-4900.	0.6	0
520	Association between Platelet Autoantibody Specificity and Response to Intravenous Immunoglobulin G in the Treatment of Patients with Immune Thrombocytopenia. <i>Blood</i> , 2006, 108, 3987-3987.	0.6	0
521	Idiopathic cyclic thrombocytopenia. <i>Blood Reviews</i> , 2005, 19, 53-59.	2.8	37
522	Human cyclic thrombocytopenia and <i>Anaplasma</i> spp. infection. <i>European Journal of Haematology</i> , 2005, 74, 182-183.	1.1	0

#	ARTICLE	IF	CITATIONS
523	Gene Expression Profiling of Multiple Patients with Cyclic Thrombocytopenia Reveals Consistent Profile.. Blood, 2005, 106, 219-219.	0.6	2
524	Long-Term Follow up of Patients with Cold Agglutinin Disease.. Blood, 2005, 106, 3710-3710.	0.6	19
525	Circulating Endothelial Cells (CEC) and Angiogenesis-Related Factors in Multiple Myeloma (MM).. Blood, 2005, 106, 5064-5064.	0.6	0
526	Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma. Cancer, 2004, 101, 1404-1413.	2.0	192
527	Clinical Features, Natural History, and Treatment Outcome of Idiopathic Cyclic Thrombocytopenia: Systematic Analysis of 51 Cases Reported in the Literature.. Blood, 2004, 104, 3929-3929.	0.6	1
528	Catastrophic thromboembolism in a patient with acute lymphoblastic leukemia and hypereosinophilia. Haematologica, 2004, 89, EIM01.	1.7	4
529	Angiogenesis in rat aortic rings stimulated by very low concentrations of serum and plasma. Angiogenesis, 2003, 6, 25-29.	3.7	20
530	Acute myelogenous leukemia in an adult with thrombocytopenia with absent radii syndrome. European Journal of Haematology, 2003, 70, 246-248.	1.1	23
531	Aplastic anemia and pure red cell aplasia associated with large granular lymphocyte leukemia. Seminars in Hematology, 2003, 40, 196-200.	1.8	44
532	EDTA-dependent lymphocyte clumping. Haematologica, 2003, 88, EIM09.	1.7	2
533	Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes. Blood, 2001, 98, 483-485.	0.6	99
534	Lymphoproliferative disease of granular T lymphocytes presenting as aplastic anemia. Blood, 2000, 96, 3644-3646.	0.6	43
535	USE OF PLEURAL FLUID PROSTATE SPECIFIC ANTIGEN IN THE DIAGNOSIS OF MALIGNANT EFFUSION FROM METASTATIC PROSTATE CANCER. Journal of Urology, 2000, 164, 459-459.	0.2	1
536	Deep Venous Thrombosis of the Arm After Intravenous Immunoglobulin Infusion: Case Report and Literature Review of Intravenous Immunoglobulin-Related Thrombotic Complications. Mayo Clinic Proceedings, 2000, 75, 83-85.	1.4	125
537	22-Year-Old Woman With Severe Microcytic Anemia. Mayo Clinic Proceedings, 2000, 75, 861-864.	1.4	7
538	Lymphoproliferative disease of granular T lymphocytes presenting as aplastic anemia. Blood, 2000, 96, 3644-3646.	0.6	3
539	Thrombocytopenia after Iron Dextran Administration in a Patient with Severe Iron Deficiency Anemia. Annals of Internal Medicine, 2000, 132, 925.	2.0	15
540	Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin. Journal of Clinical Oncology, 1999, 17, 409-409.	0.8	603

#	ARTICLE	IF	CITATIONS
541	Rectal Administration of Iodide and Propylthiouracil in the Treatment of Thyroid Storm. <i>Thyroid</i> , 1995, 5, 403-405.	2.4	47